Complete financial analysis of Cartesian Therapeutics, Inc. (RNAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cartesian Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Comforia Residential REIT, Inc (3282.T) Income Statement Analysis – Financial Results
- InCity Immobilien AG (IC8.DE) Income Statement Analysis – Financial Results
- Rubicon Water Limited (RWL.AX) Income Statement Analysis – Financial Results
- Summit Securities Limited (SUMMITSEC.BO) Income Statement Analysis – Financial Results
- Chen Hsong Holdings Limited (CHHGF) Income Statement Analysis – Financial Results
Cartesian Therapeutics, Inc. (RNAC)
About Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.00M | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 1.55M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.45M | 108.74M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 94.03% | 98.16% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 14.36M | 17.26M | 18.08M | 12.25M | 7.29M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 110.87M | 96.24M | 89.67M | 73.42M | 57.11M | 64.95M | 63.24M | 41.95M | 30.27M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | 2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 843.00K | 2.04M | 1.72M | 1.73M | 2.03M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -235.06M | 39.84M | -5.16M | -65.59M | -51.80M | -62.87M | -63.37M | -34.16M | -23.18M | -11.46M |
| EBITDA Ratio | -903.95% | 14.58% | -3.91% | -337.40% | -755.25% | -7,092.69% | -30,451.21% | -419.00% | -403.59% | -377.11% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | -332.32% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | -917.97% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | -19.00M | -609.00K | 15.97M | 1.65M | 1.86M | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -219.71M | 35.38M | -25.69M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | -844.91% | 31.94% | -30.19% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | -42.49 | 7.33 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| EPS Diluted | -42.49 | 2.98 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| Weighted Avg Shares Out | 5.17M | 4.83M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
| Weighted Avg Shares Out (Dil) | 5.17M | 4.86M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Source: https://incomestatements.info
Category: Stock Reports